CSU CANNABIDIOL (CBD) TRIALS NEWS AND UPDATES

WHAT WE KNOW SO FAR

CBD SAFETY AND PHARMACOKINETICS

• Well-tolerated in healthy dogs
• Half-life: 2-4 hours
• Oil formulation had the best bioavailability
• Reported side effects: Diarrhea and ALP elevation

PILOT EPILEPSY STUDY

• 9 dogs in treatment group
• 2.5mg/kg PO BID
• 89% of dogs in CBD group had a reduction of seizures

WHAT WE HAVE TO LEARN

• Is CBD a reliably effective anticonvulsant?
• What is the optimal dose? What is the dose range?
• Are there interactions with other medications?
• Is it safe and effective in cats?
• What is the mechanism of action?

PARTICIPANTS:
Healthy dogs with poorly controlled idiopathic epilepsy

QUALIFYING CRITERIA:
• 2 or more seizures per month for the past 3 months
• Receiving at least one routine anticonvulsant in a therapeutic dosing range

REQUIREMENTS (FULLY COVERED BY THE STUDY):
• MRI and CSF tap (general anesthesia)
• Bloodwork every 4 weeks

FOR NON-LOCAL PARTICIPANTS
We will happily work with your clinic to conduct 4 week rechecks. For more information on the trial and outside clinic participation, please contact Breonna Thomas

CONTACT:
Breonna Thomas
CSUNeuroTrials@colostate.edu
(970) 305-0455

McGrath, S., Bartner, L.R., Rao, S., Packer, R., & Gustafson, D.L. (2019). Randomized blinded controlled clinical trial to assess the effect of oral cannabidiol administration in addition to conventional antiepileptic treatment on seizure frequency in dogs with intractable idiopathic epilepsy. JAVMA, 254(7)